Publications

• Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.
  Kim, Y. H., Tavallaee, M., Sundram, U., Salva, K. A., Wood, G. S., & Horwitz, S. M. (2015). Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project. Journal of clinical oncology , 33(32), 3750-3758.
• Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2
  Ungewickell, A., Bhaduri, A., Rios, E., Reuter, J., Lee, C. S., & Khavari, P. A. (2015). Genomic analysis of mycosis fungoides and Sezary syndrome identifies recurrent alterations in TNFR2. NATURE GENETICS, 47(9), 1056-?.
• Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials
  Hoppe, R. T., Harrison, C., Tavallaee, M., Bashey, S., Sundram, U., & Kim, Y. H. (2015). Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 72(2), 286-292.
• Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials Hoppe, R. T., Harrison, C., Tavallaee, M., Bashey, S., Li, S., & Kim, Y. H. (2014). Low Dose (12 Gy) Total Skin Electron Beam Therapy (TSEBT) for Mycosis Fungoides (mf): Results of Three Phase 2 Clinical Trials. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 90, S151-S151.
  
• Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma Weng, W.-K., Armstrong, R., Arai, S., Desmarais, C., Hoppe, R., & Kim, Y. H. (2013). Minimal Residual Disease Monitoring with High-Throughput Sequencing of T Cell Receptors in Cutaneous T Cell Lymphoma. SCIENCE TRANSLATIONAL MEDICINE, 5(214).
  
• Topical Chemotherapy in Cutaneous T-cell Lymphoma Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides Lessin, S. R., Duvic, M., Guitart, J., Pandya, A. G., Strober, B. E., & Kim, Y. H. (2013). Topical Chemotherapy in Cutaneous T-cell Lymphoma Positive Results of a Randomized, Controlled, Multicenter Trial Testing the Efficacy and Safety of a Novel Mechlorethamine, 0.02%, Gel in Mycosis Fungoides. JAMA DERMATOLOGY, 149(1), 25-32.
  
• Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts Lee, C. S., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D. E., & Khavari, P. A. (2012). Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts. BLOOD, 120(16), 3288-3297.
  
• Romidepsin Is Effective in Subcutaneous Panniculitis-Like T-Cell Lymphoma Bashey, S., Krathen, M., Abdulla, F., Sundram, U., & Kim, Y. H. (2012). Romidepsin Is Effective in Subcutaneous Panniculitis-Like T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 30(24), E221-E225.
  
• Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma Horwitz, S. M., Kim, Y. H., Foss, F., Zain, J. M., Myskowski, P. L., & Duvic, M. (2012). Identification of an active, well-tolerated dose of pralatrexate in patients with relapsed or refractory cutaneous T-cell lymphoma. BLOOD, 119(18), 4115-4122.
  
• In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J. D., Czerwinski, D. K., & Levy, R. (2012). In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study. BLOOD, 119(2), 355-363.
  
• REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES Harrison, C., Young, J., Navi, D., Riaz, N., Lingala, B., & Hoppe, R. (2011). REVISITING LOW-DOSE TOTAL SKIN ELECTRON BEAM THERAPY IN MYCOSIS FUNGOIDES. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 81(4), E651-E657.
  
• In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study Kim, Y. H., Gratzinger, D., Harrison, C., Brody, J., Czerwinski, D., & Levy, R. (2010). In Situ Vaccination with TLR9 Agonist Combined with Local Radiation In Mycosis Fungoides: Analysis of Phase I/II Study. BLOOD, 116(21), 130-130.
  
• Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. Horwitz, S. M., Kim, Y. H., Foss, F. M., Zain, J. M., Myskowski, P., & Duvic, M. (2010). Identification of An Active, Well-Tolerated Dose of Pralatrexate In Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): Final Results of a Multicenter Dose-Finding Study. BLOOD, 116(21), 1154-1155.
  
• Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., & Kim, Y. H. (2010). Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 28(29), 4485-4491.
  
• In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study Brody, J. D., Ai, W. Z., Czerwinski, D. K., Torchia, J. A., Levy, M., & Levy, R. (2010). In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study. JOURNAL OF CLINICAL ONCOLOGY, 28(28), 4324-4332.
  
• Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome Woo, D. K., Jones, C. R., Vanoli-Storz, M. N., Kohler, S., Reddy, S., & Kim, Y. H. (2009). Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma Characterization of Clinical Subset With Worse Outcome. ARCHIVES OF DERMATOLOGY, 145(6), 667-674.
  
• Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial Horwitz, S., Duvic, M., Kim, Y., Chance, L., Myskowski, P., & O'Connor, O. (2008). Low dose pralatrexate (PDX) is active in cutaneous T-cell lymphoma: Preliminary results of a multi-center dose finding trial. ANNALS OF ONCOLOGY, 19, 162-162.
  
• TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC) Kim, Y. H., Willemze, R., Pimpinelli, N., Whittaker, S., Olsens, E. A., & Hoppe, R. T. (2007). TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). BLOOD, 110(2), 479-484.
  
• Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma Kim, Y. H., Duvic, M., Obitz, E., Gniadecki, R., Iversen, L., & Knox, S. J. (2007). Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. BLOOD, 109(11), 4655-4662.
  
• TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. Kim, Y., Girardi, M., Duvic, M., Kuzel, T., Rook, A., & Schmalbach, T. (2004). TLR9 agonist immunomodulator treatment of cutaneous T-cell lymphoma (CTCL) with CPG7909. BLOOD, 104(11), 212A-213A.
  
• HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma Kim, Y. H., Obitz, E., Iversen, L., Oesterborg, A., Whittaker, S., & Knox, S. J. (2004). HuMax-CD4, fully human monoclonal antibody: Phase II trial in cutaneous T cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 122(3), A57-A57.
  
• Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides de Coninck, E., Kim, Y., Varghese, A., & Hoppe, R. (2001). Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 117(2), 534-534.
  
• Lymph node involvement by mycosis fungoides and Sezary syndrome mimicking angioimmunoblastic T-cell Lymphoma LeBlanc, R. E., Lefterova, M. I., Suarez, C. J., Tavallaee, M., Kim, Y. H., & Gratzinger, D. (2015). Lymph node involvement by mycosis fungoides and Sezary syndrome mimicking angioimmunoblastic T-cell Lymphoma. HUMAN PATHOLOGY, 46(9), 1382-1389.
  
• Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old Boy Soon, C. Wm., Link, M., Kim, Y. H., & Kim, J. (2015). Primary Cutaneous Gamma-Delta T-Cell Lymphoproliferative Disorder in a 3-Year-Old Boy. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 37(7), 567-569.
  
• Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Dummer, R., Duvic, M., Scarisbrick, J., Olsen, E. A., Rozati, S., & Kim, Y. H. (2014). Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous t-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome). Annals of oncology , 25(9), 1807-1812.
  
• Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders Samols, M. A., Su, A., Ra, S., Cappel, M. A., Louissant, A., & Gratzinger, D. (2014). Intralymphatic Cutaneous Anaplastic Large Cell Lymphoma/Lymphomatoid Papulosis Expanding the Spectrum of CD30-positive Lymphoproliferative Disorders. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 38(9), 1203-1211.
  
• Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now? Scarisbrick, J. J., Kim, Y. H., Whittaker, S. J., Wood, G. S., Vermeer, M. H., & Quaglino, P. (2014). Prognostic factors, prognostic indices and staging in mycosis fungoides and Sezary syndrome: where are we now?. BRITISH JOURNAL OF DERMATOLOGY, 170(6), 1226-1236.
  
• Multicenter Case Series of Indolent Small/Medium-Sized CD8(+) Lymphoid Proliferations With Predilection for the Ear and Face Li, J. Y., Guitart, J., Pulitzer, M. P., Subtil, A., Sundram, U., & Querfeld, C. (2014). Multicenter Case Series of Indolent Small/Medium-Sized CD8(+) Lymphoid Proliferations With Predilection for the Ear and Face. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 36(5), 402-408.
  
• Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve diagnosis in cutaneous T cell lymphoma Rozati, S., Weng, W., Tavallaee, M., Kim, J., Rieger, K., & Kim, Y. H. (2014). Utility of high-throughput sequencing of T cell receptor gene rearrangement to improve diagnosis in cutaneous T cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 134, S96-S96.
  
• A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides Bashey, S., Tavallaee, M., Duvic, M., Dabaja, B., Talpur, R., & Kim, Y. H. (2014). A multicenter, open-label, randomized, phase I/II study evaluating the safety and efficacy of low-dose (12 Gy) total skin electron beam therapy (TSEBT) combined with vorinostat versus low-dose TSEBT monotherapy in patients with mycosis fungoides. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 134, S104-S104.
  
• Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome Querfeld, C., Rosen, S. T., Guitart, J., Duvic, M., Kim, Y. H., & Kuzel, T. M. (2014). Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sezary syndrome. BLOOD, 123(8), 1159-1166.
  
• Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course Toward Recognition of a Distinct Clinicopathologic Entity Metcalf, R. A., Bashey, S., Wysong, A., Kim, J., Kim, Y. H., & Gratzinger, D. (2013). Intravascular ALK-negative Anaplastic Large Cell Lymphoma With Localized Cutaneous Involvement and an Indolent Clinical Course Toward Recognition of a Distinct Clinicopathologic Entity. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 37(4), 617-623.
  
• Clonal Identity and Differences in Primary Cutaneous B-Cell Lymphoma Occurring at Different Sites or Time Points in the Same Patient Fujiwara, M., Morales, A. V., Seo, K., Kim, Y. H., Arber, D. A., & Sundram, U. N. (2013). Clonal Identity and Differences in Primary Cutaneous B-Cell Lymphoma Occurring at Different Sites or Time Points in the Same Patient. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 35(1), 11-18.
  
• Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin Kim, Y. H., Demierre, M.-F., Kim, E. J., Lerner, A., Rook, A. H., & Whittaker, S. (2013). Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. LEUKEMIA & LYMPHOMA, 54(2), 284-289.
  
• Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression Krathen, M., Sundram, U., Bashey, S., Sutherland, K., Salva, K., & Kim, Y. H. (2012). Brentuximab Vedotin Demonstrates Significant Clinical Activity in Relapsed or Refractory Mycosis Fungoides with Variable CD30 Expression. BLOOD, 120(21).
  
• Cutaneous gamma delta T-cell Lymphomas A Spectrum of Presentations With Overlap With Other Cytotoxic Lymphomas Guitart, J., Weisenburger, D. D., Subtil, A., Kim, E., Wood, G., & Kim, Y. H. (2012). Cutaneous gamma delta T-cell Lymphomas A Spectrum of Presentations With Overlap With Other Cytotoxic Lymphomas. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 36(11), 1656-1665.
  
• Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels Bashey, S., Krathen, M., Sutherland, K., Sundram, U., Lingala, B., & Kim, Y. (2012). Exploratory study of brentuximab vedotin (SGN-35), a novel monoclonal antibody-drug-conjugate against CD30, in mycosis fungoides (MF) and Sezary syndrome (SS) demonstrates clinical responses regardless of CD30 expression levels. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, S95-S95.
  
• Transcriptome sequencing in Sezary Syndrome identifies novel Sezary cell-associated transcripts Lee, C., Ungewickell, A., Bhaduri, A., Qu, K., Webster, D., & Khavari, P. A. (2012). Transcriptome sequencing in Sezary Syndrome identifies novel Sezary cell-associated transcripts. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 132, S29-S29.
  
• A Comparative Analysis of Cutaneous Marginal Zone Lymphoma and Cutaneous Chronic Lymphocytic Leukemia Levin, C., Mirzamani, N., Zwerner, J., Kim, Y., Schwartz, E. J., & Sundram, U. (2012). A Comparative Analysis of Cutaneous Marginal Zone Lymphoma and Cutaneous Chronic Lymphocytic Leukemia. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 34(1), 18-23.
  
• Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations Mehta, N., Wayne, A. S., Kim, Y. H., Hale, G. A., Alvarado, C. S., & Horwitz, S. (2012). Bexarotene Is Active Against Subcutaneous Panniculitis-Like T-Cell Lymphoma in Adult and Pediatric Populations. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 12(1), 20-25.
  
• EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma Kempf, W., Pfaltz, K., Vermeer, M. H., Cozzio, A., Ortiz-Romero, P. L., & Willemze, R. (2011). EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. BLOOD, 118(15), 4024-4035.
  
• A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint Bashey, S., Harrison, C., Navi, D., Lingala, B., Armstrong, R., & Hoppe, R. (2011). A prospective trial of low-dose total skin electron beam therapy in mycosis fungoides and proposal of a new clinically meaningful endpoint. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 9, 3-3.
  
• The frequency of dual TCR-PCR clonality in granulomatous disorders Dabiri, S., Morales, A., Ma, L., Sundram, U., Kim, Y. H., & Kim, J. (2011). The frequency of dual TCR-PCR clonality in granulomatous disorders. JOURNAL OF CUTANEOUS PATHOLOGY, 38(9), 704-709.
  
• Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma Querfeld, C., Kuzel, T. M., Kim, Y. H., Porcu, P., Duvic, M., & Rosen, S. T. (2011). Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma. LEUKEMIA & LYMPHOMA, 52(8), 1474-1480.
  
• Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer Olsen, E. A., Whittaker, S., Kim, Y. H., Duvic, M., Prince, H. M., & Vonderheid, E. C. (2011). Clinical End Points and Response Criteria in Mycosis Fungoides and Sezary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. JOURNAL OF CLINICAL ONCOLOGY, 29(18), 2598-2607.
  
• The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides Navi, D., Riaz, N., Levin, Y. S., Sullivan, N. C., Kim, Y. H., & Hoppe, R. T. (2011). The Stanford University Experience With Conventional-Dose, Total Skin Electron-Beam Therapy in the Treatment of Generalized Patch or Plaque (T2) and Tumor (T3) Mycosis Fungoides. ARCHIVES OF DERMATOLOGY, 147(5), 561-567.
  
• Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) Olsen, E. A., Rook, A. H., Zic, J., Kim, Y., Porcu, P., & Duvic, M. (2011). Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC). JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 64(2), 352-404.
  
• Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma Kim, Y. H., Girardi, M., Duvic, M., Kuzel, T., Link, B. K., & Rook, A. H. (2010). Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 63(6), 975-983.
  
• Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective Kim, Y. H. (2010). Multidisciplinary Care in the Management of Patients With Cutaneous Lymphoma: A Perspective. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 10, S106-S108.
  
• Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses Zhang, B., Beck, A. H., Taube, J. M., Kohler, S., Seo, K., & Zehnder, J. L. (2010). Combined Use of PCR-Based TCRG and TCRB Clonality Tests on Paraffin-Embedded Skin Tissue in the Differential Diagnosis of Mycosis Fungoides and Inflammatory Dermatoses. JOURNAL OF MOLECULAR DIAGNOSTICS, 12(3), 320-327.
  
• T-Cell Receptor PCR from Separate Biopsies Distinguishes Granulomatous Dermatitis from Granulomatous Mycosis Fungoides Dabiri, S., Arber, D. A., Kim, Y. H., Sundram, U. N., & Kim, J. (2010). T-Cell Receptor PCR from Separate Biopsies Distinguishes Granulomatous Dermatitis from Granulomatous Mycosis Fungoides. LABORATORY INVESTIGATION, 90, 112A-112A.
  
• Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement Kim, Y. H., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., & Whittaker, S. (2009). Clinically Significant Responses Achieved with Romidepsin in 37 Patient with Cutaneous T-Cell Lymphoma (CTCL) with Blood Involvement. BLOOD, 114(22), 1050-1050.
  
• A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders Duvic, M., Reddy, S. A., Pinter-Brown, L., Korman, N. J., Zic, J., & Kim, Y. H. (2009). A Phase II Study of SGN-30 in Cutaneous Anaplastic Large Cell Lymphoma and Related Lymphoproliferative Disorders. CLINICAL CANCER RESEARCH, 15(19), 6217-6224.
  
• Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells Mattoch, I. W., Fulton, R., Kim, Y., Hoppe, R., Warnke, R. A., & Sundram, U. N. (2009). Cutaneous Peripheral T-Cell Lymphoma Associated With a Proliferation of B Cells. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 131(6), 810-819.
  
• Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin Weinberg, O. K., Ma, L., Seo, K., Beck, A. H., Pai, R. K., & Arber, D. A. (2009). Low Stage Follicular Lymphoma: Biologic and Clinical Characterization According to Nodal or Extranodal Primary Origin. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 33(4), 591-598.
  
• The morphologic and immunohistochemical overlap between cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia Levin, C., Mizramani, N., Zwerner, J., Kim, Y., & Sundram, U. (2009). The morphologic and immunohistochemical overlap between cutaneous marginal zone lymphoma and cutaneous chronic lymphocytic leukemia. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 129, S53-S53.
  
• Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab Morales, A. V., Advani, R., Horwitz, S. M., Riaz, N., Reddy, S., & Kim, Y. H. (2008). Indolent primary cutaneous B-cell lymphoma: Experience using systemic rituximab. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(6), 953-957.
  
• Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study Kim, Y., Whittaker, S., Demierre, M. F., Rook, A. H., Lerner, A., & Prentice, A. G. (2008). Clinically Significant Responses Achieved with Romidepsin in Treatment-Refractory Cutaneous T-Cell Lymphoma: Final Results from a Phase 2B, International, Multicenter, Registration Study. BLOOD, 112(11), 103-104.
  
• Cytologic Evaluation of Lymphadenopathy Associated With Mycosis Fungoides and Sezary Syndrome Role of Immunophenotypic and Molecular Ancillary Studies Pai, R. K., Mullins, F. M., Kim, Y. H., & Kong, C. S. (2008). Cytologic Evaluation of Lymphadenopathy Associated With Mycosis Fungoides and Sezary Syndrome Role of Immunophenotypic and Molecular Ancillary Studies. CANCER CYTOPATHOLOGY, 114(5), 323-332.
  
• Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease Lee, J., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., & Kim, Y. H. (2008). Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 59(4), 706-712.
  
• Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates Morales, A. V., Arber, D. A., Seo, K., Kohler, S., Kim, Y. H., & Sundram, U. N. (2008). Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates. AMERICAN JOURNAL OF DERMATOPATHOLOGY, 30(5), 425-430.
  
• European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas Senff, N. J., Noordijk, E. M., Kim, Y. H., Bagot, M., Berti, E., & Willemze, R. (2008). European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. BLOOD, 112(5), 1600-1609.
  
• Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma Xie, X., Sundram, U., Natkunam, Y., Kohler, S., Hoppe, R. T., & Hsi, E. D. (2008). Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. MODERN PATHOLOGY, 21(6), 653-659.
  
• International trial confirms romidpesin efficacy in refractory CTCL patients Prentice, A., Whittaker, S., Kim, Y., Kim, E., LERNER, A., & McCulloch, W. (2008). International trial confirms romidpesin efficacy in refractory CTCL patients. ANNALS OF ONCOLOGY, 19, 116-116.
  
• An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML Bullinger, L., Doehner, K., Kranz, R., Stirner, C., Froeling, S., & Pollack, J. R. (2008). An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML. BLOOD, 111(9), 4490-4495.
  
• Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. Horwitz, S. M., Olsen, E. A., Duvic, M., Porcu, P., & Kim, Y. H. (2008). Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach. Journal of the National Comprehensive Cancer Network , 6(4), 436-442.
  
• Radiation therapy is an effective treatment for refractory Woringer-Kolopp disease Lee, I. L., Viakhireva, N., Cesca, C., Lee, P., Kohler, S., & Kim, Y. (2008). Radiation therapy is an effective treatment for refractory Woringer-Kolopp disease. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 128, S70-S70.
  
• Romidepsin has activity in refractory ctcl: an international multicenter study Whittaker, S., Scarisbrick, J., Kim, Y., Reddy, S., Kim, E., & Prentice, A. (2008). Romidepsin has activity in refractory ctcl: an international multicenter study. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 128, S74-S74.
  
• Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome Woo, D., Jones, C., Vanoli-Storz, M., Kohler, S., Reddy, S., & Kim, Y. (2007). Prognostic factors in primary cutaneous anaplastic large cell lymphoma: Clinical and molecular characterization of a subset with worse outcome. BLOOD, 110(11), 1045A-1045A.
  
• Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter study Kim, Y. H., Reddy, S., Kim, E. J., Rook, A. H., Lerner, A., & Prentice, A. G. (2007). Romidepsin (depsipeptide) induces clinically significant responses in treatment-refractory CTCL: An International, Multicenter study. BLOOD, 110(11), 44A-44A.
  
• T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides Thurber, S. E., Zhang, B., Kim, Y. H., Schrijver, I., Zehnder, J., & Kohler, S. (2007). T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 57(5), 782-790.
  
• Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC) Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., & Whittaker, S. (2007). Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). BLOOD, 110(6), 1713-1722.
  
• Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis Richmond, H., Zwerner, J., Kim, Y., & Fiorentino, D. (2007). Nephrogenic systemic fibrosis - Relationship to gadolinium and response to photopheresis. ARCHIVES OF DERMATOLOGY, 143(8), 1025-1030.
  
• Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., & Duvic, M. (2007). Phase IIB multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 25(21), 3109-3115.
  
• Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts Huang, K. P., Weinstock, M. A., Clarke, C. A., McMillan, A., Hoppe, R. T., & Kim, Y. H. (2007). Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts. ARCHIVES OF DERMATOLOGY, 143(1), 45-50.
  
• Preliminary report on a phase I/II study of intraturnoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas. Ai, W. Y. Z., Kim, Y., Hoppe, R. T., Shah, S., Horning, S. J., & Levy, R. (2006). Preliminary report on a phase I/II study of intraturnoral injection of PF-3512676 (CpG 7909), a TLR9 agonist, combined with radiation in recurrent low-grade lymphomas. BLOOD, 108(11), 767A-768A.
  
• Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders. Duvic, M., Kim, Y., Reddy, S., Forero-Torres, A., Pinter-Brown, L. C., & Sievers, E. (2006). Phase II preliminary results of SGN-30 (anti-CD30 mAb) in patients with CD30+lymphoproliferative disorders. BLOOD, 108(11), 773A-773A.
  
• Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology Jayaraman, A. G., Cassarino, D., Advani, R., Kim, Y. H., Tsai, E., & Kohler, S. (2006). Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology. JOURNAL OF CUTANEOUS PATHOLOGY, 33, 6-11.
  
• Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography Tsai, E. Y., Taur, A., Espinosa, L., Quon, A., Johnson, D., & Kim, Y. H. (2006). Staging accuracy in mycosis fungoides and Sezary syndrome using integrated positron emission tomography and computed tomography. ARCHIVES OF DERMATOLOGY, 142(5), 577-584.
  
• Phase II preliminary results suggest SGN-30 (Anti-CD30 monoclonal antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma Duvic, M., Kunishige, J., Kim, Y., Reddy, S., Forero-Torres, A., & Barton, J. (2006). Phase II preliminary results suggest SGN-30 (Anti-CD30 monoclonal antibody) is active and well-tolerated in patients with cutaneous anaplastic large cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, 45-45.
  
• The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma Reddy, S., Kohler, S., Horwitz, S., Sutherland, K., Hoppe, R. T., & Kim, Y. H. (2006). The Stanford experience with utilizing the new WHO classification of cutaneous lymphomas for cutaneous B cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 126, 44-44.
  
• Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. Molina, A. M., Advani, R., Reddy, S., Hoppe, R., Friedberg, J. W., & Horwitz, S. M. (2005). Bexarotene is highly active in the treatment of subcutaneous Panniculitis-like T-cell lymphoma. BLOOD, 106(11), 934A-934A.
  
• Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study Sundram, U., Kim, Y., Mraz-Gernhard, S., Hoppe, R., Natkunam, Y., & Kohler, S. (2005). Expression of the bcl-6 and MUM1/IRF4 proteins correlate with overall and disease-specific survival in patients with primary cutaneous large B-cell lymphoma: a tissue microarray study. JOURNAL OF CUTANEOUS PATHOLOGY, 32(3), 227-234.
  
• Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients Beynet, D. P., Wee, S. A., Horwitz, S. S., Kohler, S., Horning, S., & Kim, Y. H. (2004). Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients. ARCHIVES OF DERMATOLOGY, 140(9), 1140-1146.
  
• CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma Liu, H. L., Hoppe, R. T., Kohler, S., Harvell, J. D., Reddy, S., & Kim, Y. H. (2003). CD30(+) cutaneous lymphoproliferative disorders: The Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 49(6), 1049-1058.
  
• Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression Kim, Y. H., Liu, H. L., Mraz-Gernhard, S., Varghese, A., & Hoppe, R. T. (2003). Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome - Clinical prognostic factors and risk for disease progression. ARCHIVES OF DERMATOLOGY, 139(7), 857-866.
  
• Gene expression profiles of cutaneous B cell lymphoma Storz, M. N., van de Rijn, M., Kim, Y. H., Mraz-Gernhard, S., Hoppe, R. T., & Kohler, S. (2003). Gene expression profiles of cutaneous B cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 120(5), 865-870.
  
• Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience Kim, Y. H., Martinez, G., Varghese, A., & Hoppe, R. T. (2003). Topical nitrogen mustard in the management of mycosis fungoides - Update of the Stanford experience. ARCHIVES OF DERMATOLOGY, 139(2), 165-173.
  
• Management with topical nitrogen mustard in mycosis fungoides. Kim, Y. H. (2003). Management with topical nitrogen mustard in mycosis fungoides. Dermatologic therapy, 16(4), 288-298.
  
• The largest single-center US study of cutaneous CD30+lymphoproliferative disorders Liu, H., Kohler, S., Harvell, J., Hoppe, R., & Kim, Y. (2002). The largest single-center US study of cutaneous CD30+lymphoproliferative disorders. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 119(1), 237-237.
  
• Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK (R)) Duvic, M., Kuzel, T., Olsen, E. A., Martin, A. G., Foss, F. M., & Liepa, A. (2002). Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK (R)). CLINICAL LYMPHOMA, 2(4), 222-228.
  
• Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea Su, L. D., Kim, Y. H., LeBoit, P. E., Swetter, S. M., & Kohler, S. (2002). Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea. JOURNAL OF CUTANEOUS PATHOLOGY, 29(3), 135-141.
  
• Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases Harvell, J. D., Vaseghi, M., Natkunam, Y., Kohler, S., & Kim, Y. (2002). Large atypical cells of lymphomatoid papulosis are CD56-negative: a study of 18 cases. JOURNAL OF CUTANEOUS PATHOLOGY, 29(2), 88-92.
  
• Natural killer/natural killer-like T-Cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course Mraz-Gernhard, S., Natkunam, Y., Hoppe, R. T., Leboit, P., Kohler, S., & Kim, Y. H. (2001). Natural killer/natural killer-like T-Cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course. JOURNAL OF CLINICAL ONCOLOGY, 19(8), 2179-2188.
  
• Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides de Coninck, E. C., Kim, Y. H., Varghese, A., & Hoppe, R. T. (2001). Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides. JOURNAL OF CLINICAL ONCOLOGY, 19(3), 779-784.
  
• Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., & Nichols, J. (2001). Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. JOURNAL OF CLINICAL ONCOLOGY, 19(2), 376-388.
  
• Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases Natkunam, Y., Warnke, R. A., Haghighi, B., Su, L. D., Le Boit, P. E., & Kohler, S. (2000). Co-expression of CD56 and CD30 in lymphomas with primary presentation in the skin: clinicopathologic, immunohistochemical and molecular analyses of seven cases. JOURNAL OF CUTANEOUS PATHOLOGY, 27(8), 392-399.
  
• Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides Chui, C. T., Hoppe, R. T., Kohler, S., & Kim, Y. H. (1999). Epidermotropic cutaneous B-cell lymphoma mimicking mycosis fungoides. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 41(2), 271-274.
  
• Mycosis fungoides and the Sezary syndrome Kim, Y. H., & Hoppe, R. T. (1999). Mycosis fungoides and the Sezary syndrome. SEMINARS IN ONCOLOGY, 26(3), 276-289.
  
• Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides Chinn, D. M., Chow, S., Kim, Y. H., & Hoppe, R. T. (1999). Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 43(5), 951-958.
  
• Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides Kim, Y. H., Chow, S., Varghese, A., & Hoppe, R. T. (1999). Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. ARCHIVES OF DERMATOLOGY, 135(1), 26-32.
  
• Role of histology in providing prognostic information in mycosis fungoides SMOLLER, B. R., Detwiler, S. P., Kohler, S., Hoppe, R. T., & Kim, Y. H. (1998). Role of histology in providing prognostic information in mycosis fungoides. JOURNAL OF CUTANEOUS PATHOLOGY, 25(6), 311-315.
  
• Mycosis fungoides in young patients: Clinical characteristics and outcome Crowley, J. J., Nikko, A., Varghese, A., Hoppe, R. T., & Kim, Y. H. (1998). Mycosis fungoides in young patients: Clinical characteristics and outcome. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 38(5), 696-701.
  
• Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF). Liepa, A., Bennett, C. L., Yarnold, P. R., Enas, N., Lozano, J., & Nichols, J. (1997). Changes in quality of life (QOL) for patients (pts) enrolled in a phase III trial of treatment with a diphtheria toxin fusion protein (DAB(389)IL-2) for mycosis fungoides (MF). BLOOD, 90(10), 3924-3924.
  
• Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal Kohler, S., Kim, Y. H., & SMOLLER, B. R. (1997). Histologic criteria for the diagnosis of erythrodermic mycosis fungoides and Sezary syndrome: A critical reappraisal. JOURNAL OF CUTANEOUS PATHOLOGY, 24(5), 292-297.
  
• Blastomycosis-like pyoderma in a man with AIDS Crowley, J. J., & Kim, Y. H. (1997). Blastomycosis-like pyoderma in a man with AIDS. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 36(4), 633-634.
  
• Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis Kim, Y. H., Jensen, R. A., WATANABE, G. L., Varghese, A., & Hoppe, R. T. (1996). Clinical stage IA (limited patch and plaque) mycosis fungoides - A long-term outcome analysis. ARCHIVES OF DERMATOLOGY, 132(11), 1309-1313.
  
• Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma Wood, G. S., Salvekar, A., Schaffer, J., CROOKS, C. F., HENGHOLD, W., & SMOLLER, B. R. (1996). Evidence against a role for human T-cell lymphotrophic virus type I (HTLV-I) in the pathogenesis of American cutaneous T-cell lymphoma. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 107(3), 301-307.
  
• Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30(+) primary cutaneous lymphoproliferative disorders and Hodgkin's disease Wood, G. S., Hardman, D. L., Boni, R., Dummer, R., Kim, Y. H., & Burg, G. (1996). Lack of the t(2;5) or other mutations resulting in expression of anaplastic lymphoma kinase catalytic domain in CD30(+) primary cutaneous lymphoproliferative disorders and Hodgkin's disease. BLOOD, 88(5), 1765-1770.
  
• REASSESSMENT OF HISTOLOGIC PARAMETERS IN THE DIAGNOSIS OF MYCOSIS-FUNGOIDES SMOLLER, B. R., Bishop, K., Glusac, E., Kim, Y. H., & Hendrickson, M. (1995). REASSESSMENT OF HISTOLOGIC PARAMETERS IN THE DIAGNOSIS OF MYCOSIS-FUNGOIDES. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 19(12), 1423-1430.
  
• CUTANEOUS GNATHOSTOMIASIS Crowley, J. J., & Kim, Y. H. (1995). CUTANEOUS GNATHOSTOMIASIS. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 33(5), 825-828.
  
• PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME Kim, Y. H., Bishop, K., Varghese, A., & Hoppe, R. T. (1995). PROGNOSTIC FACTORS IN ERYTHRODERMIC MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME. ARCHIVES OF DERMATOLOGY, 131(9), 1003-1008.
  
• LYMPHOCYTE ANTIGEN ABNORMALITIES IN INFLAMMATORY DERMATOSES SMOLLER, B. R., Bishop, K., Glusac, E. J., Bhargava, V., Kim, Y. H., & Warnke, R. A. (1995). LYMPHOCYTE ANTIGEN ABNORMALITIES IN INFLAMMATORY DERMATOSES. APPLIED IMMUNOHISTOCHEMISTRY, 3(2), 127-131.
  
• REASSESSMENT OF LYMPHOCYTE IMMUNOPHENOTYPING IN THE DIAGNOSIS OF PATCH AND PLAQUE STAGE LESIONS OF MYCOSIS-FUNGOIDES SMOLLER, B. R., Bishop, K., Glusac, E. J., Kim, Y. H., Bhargava, V., & Warnke, R. A. (1995). REASSESSMENT OF LYMPHOCYTE IMMUNOPHENOTYPING IN THE DIAGNOSIS OF PATCH AND PLAQUE STAGE LESIONS OF MYCOSIS-FUNGOIDES. APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 3(1), 32-36.
  
• CONSTITUTIVE ACTIVATION OF THE COLLAGENASE PROMOTER IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA FIBROBLASTS - ROLE OF ENDOGENOUSLY ACTIVATED AP-1 Unemori, E. N., Mauch, C., Hoeffler, W., Kim, Y., Amento, E. P., & BAUER, E. A. (1994). CONSTITUTIVE ACTIVATION OF THE COLLAGENASE PROMOTER IN RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA FIBROBLASTS - ROLE OF ENDOGENOUSLY ACTIVATED AP-1. EXPERIMENTAL CELL RESEARCH, 211(2), 212-218.
  
• Autoimmunity to anchoring fibrils. Kim, Y. H., & Woodley, D. T. (1994). Autoimmunity to anchoring fibrils. Advances in dermatology, 9, 61-77.
  
• A DOUBLE-BLIND COMPARISON OF ADHESIVE BANDAGES WITH THE USE OF UNIFORM SUCTION BLISTER WOUNDS Woodley, D. T., & Kim, Y. H. (1992). A DOUBLE-BLIND COMPARISON OF ADHESIVE BANDAGES WITH THE USE OF UNIFORM SUCTION BLISTER WOUNDS. ARCHIVES OF DERMATOLOGY, 128(10), 1354-1357.
  
• RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA PHENOTYPE IS PRESERVED IN XENOGRAFTS USING SCID MICE - DEVELOPMENT OF AN EXPERIMENTAL INVIVO MODEL Kim, Y. H., Woodley, D. T., WYNN, K. C., GIOMI, W., & BAUER, E. A. (1992). RECESSIVE DYSTROPHIC EPIDERMOLYSIS-BULLOSA PHENOTYPE IS PRESERVED IN XENOGRAFTS USING SCID MICE - DEVELOPMENT OF AN EXPERIMENTAL INVIVO MODEL. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 98(2), 191-197.
  
• H-1-NMR SPECTROSCOPY - AN APPROACH TO EVALUATION OF DISEASED SKIN INVIVO Kim, Y. H., Orenberg, E. K., Faull, K. F., WADEJARDETZKY, N. G., & Jardetzky, O. (1989). H-1-NMR SPECTROSCOPY - AN APPROACH TO EVALUATION OF DISEASED SKIN INVIVO. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 92(2), 210-216.